Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2016 12:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Presents Corporate and Clinical Updates at Investor and Analyst Day

PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
April 22, 2016 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces SPEAR T-cells™ Brand for Proprietary Technology

PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
April 22, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Appoints Leading Immunotherapy Experts from United States and Europe to Inaugural Scientific Advisory Board

PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
April 20, 2016 09:10 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Host Analyst and Investor Day on April 22, 2016

PHILADELPHIA and OXFORD, U.K., April 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
April 18, 2016 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces New Vice President of Business Development, Wenyong Wang

PHILADELPHIA and OXFORD, United Kingdom, April 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
April 07, 2016 09:02 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer

PHILADELPHIA and OXFORD, United Kingdom, April 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
March 30, 2016 07:40 ET | Source: Adaptimmune Therapeutics plc

U.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

PHILADELPHIA and OXFORD, United Kingdom, March 30, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
March 17, 2016 07:56 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015

PHILADELPHIA and OXFORD, United Kingdom, March 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in the use of T-cell therapy to...
March 02, 2016 10:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at Cowen and Company’s 36th Annual Health Care Conference

PHILADELPHIA and OXFORD, United Kingdom, March 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
February 17, 2016 14:07 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at the RBC Capital Markets Global Healthcare Conference

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer,...